Abstract 22 23
To elucidate the mode of viral persistence in primate lentivirus-infected individuals during 24 combination antiretroviral therapy (cART), four simian immunodeficiency virus 25 (SIV)239-infected monkeys were treated with cART for 1 year. The viral env genes prepared 26 from total RNA extracted from the mesenteric lymph nodes by single genome amplification 27 were assessed at the completion of therapy. Analyses of nucleotide substitution and 28 phylogeny revealed no viral evolution during cART. 29 30 simian immunodeficiency virus (SIV)/macaque model, which allows for systemic 48 examination, the identification of the viral reservoir and the mechanism of viral holding have 49 not been studied in detail. SIV239-infected rhesus macaques for 1 year (18). Although the plasma viral RNA loads of 55 the animals were suppressed to below the assay detection limit during the period of 56 chemotherapy, systemic analysis conducted at the completion of the therapy revealed viral 57 RNA present in lymphatic tissues, especially in mesenteric and splenic lymph nodes (MLN 58 and SLN, respectively) at high titers. Reasoning that any possible mode(s) of viral 59 persistence should be in operation in tissues with high levels of viral RNA expression, we 60 investigated viral genes in these tissues. 61
It is expected that viral genes accumulate nucleotide substitutions in proportion to 62 time post-infection in individuals not undergoing therapy due to continuous virus replication 63 mediated by the error-prone viral reverse transcriptase. Such mutation rates have indeed been 64 observed in the V3 loop of env, p17 of gag (20), and C2-C5 region of env (30) in HIV-1 65 infected patients as well as in the env gene from monkeys experimentally infected with SIV 66 (5, 19). We hypothesized that viral genes would accumulate mutations if the virus was 67 continuously replicating in the reservoir despite the presence of antivirals. 68
First, to ascertain whether such accumulation of mutations took place to a 69 detectable magnitude in our experimental system, SIV239, a molecularly cloned virus, was 70 used to infect macaques for 1 year, and we periodically sampled viral genes from the 71 untreated control animal (MM521). To reveal ongoing expression of viral genes at sampling, 72 total RNA was extracted from plasma samples collected at 8, 18, 42, and 68 weeks 73 post-infection (wpi) and examined. Single genome amplification (SGA) (29) was used to 74 amplify present viral genes and to avoid selective amplification of a particular genotype or 75 recombination between genotypes during polymerase chain reaction (PCR). Using nested 76 5 PCR, we amplified the entire env gene, which accumulates nucleotide substitutions in the 77 greatest numbers, following reverse transcription of cDNA from the extracted RNA. The 78 initial cycles of PCR were carried out utilizing the following primers: forward, SIV20F 79 (5'-ctc cag gac tag cat aaa tgg-3'); reverse, SHenv9R (5'-ggg tat cta aca tat gcc tc-3'). 80
Successive PCR cycles were run with the following primers: forward, SIV21F (5'-ctc tct cag 81 cta tac cgc cc-3'); reverse, SHenv8R (5'-gcc ttc ttc ctt ttc taa g-3'). The PCR products from 82 an average of 12 independent reactions per time point were directly subjected to sequencing. 83
We computed the number of mutations in each SGA clone obtained from plasma 84 samples of an untreated monkey (MM521) through a comparison with that of the inoculum 85 virus ( Fig. 1) . A linear relationship with a coefficient of 1.25 × 10 -4 (r 2 = 0.8503, p < 0.0001; 86
GraphPad Prism, La Jolla, CA, USA) was revealed between the number of mutations in the 87 SGA clones and the time post-infection. Using the coefficient, the cumulative mutations per 88 annum was determined to be 6.5 × 10 -3 substitutions/site/year, a comparable figure to those of 89 SIV and HIV reported previously (9 × 10 -3 (5, 19) and 6.0 × 10 -3 (29) substitutions/site/year, 90 respectively). The accuracy of the "molecular clock" in our experimental setting prompted us 91 to examine viral RNA extracted from the lymph nodes of animals that underwent cART for 1 92
year. 93
Total RNA was extracted from the MLN of four treated animals and one untreated 94 animal as well as the SLN of one of the treated animals (MM530) at the completion of the 95 observation period and used as template for PCR; the products were subjected to sequence 96 analysis as described above. On average, 10 sequences were obtained from each sample ( Fig.  97 2A and Table) . The number of mutations observed in the env gene from MM521 (untreated) 98 was, on average, 25 of 2700 bases. In contrast, the number in treated animals was on average 99 6 1.5 of 2700 bases (Table) . The difference in the number of mutations in env between the 100 plasma and MLN samples at 68 wpi (at necropsy) in the untreated animal, MM521, was 101 statistically insignificant (p > 0.05; Fig. 2A ), justifying our comparison of these two distinct 102 anatomical compartments. Thus, we proceeded to compare the substitution numbers in the 103 plasma at 8 wpi, immediately before the onset of cART, with those from the lymph nodes of 104 animals treated with cART at necropsy (61-65 wpi). Nucleotide substitutions in the env gene 105 in both plasma and the MLN of the untreated animal (MM521) at 68 wpi increased compared 106 to that in plasma at 8 wpi (p < 0.0001). In contrast, those in the MLN of treated animals at the 107 completion of cART were unchanged (MM528 and SLN of MM530) or decreased 108 significantly (MM491, MM499, and MLN of MM530) ( Fig. 2A ). The results indicated that 109 virus did not accumulate further mutations beyond those obtained by 8 wpi. 110
As the samples were collected from animals at various time points post-infection, 111 the numbers depicted in Fig demonstrated that viral evolution did not take place in SIV239-infected rhesus macaques 144 during cART. Analysis of the env genes in the peripheral blood mononuclear cells and 145 gut-associated lymphatic tissues obtained from HIV-1 patients in cART also found no 146 evidence of de novo viral replication (11). 147
In contrast, other studies have reported continuous virus replication during 148 combined chemotherapy (2, 37). One possible explanation of this discrepancy is the thorough 149 suppression of the plasma viral burden, < 20 copies/mL at necropsy that was achieved in this 150 study (18). De novo virus replication was detected in HIV-1 patients whose plasma viral 151 RNA burdens ranged from 20 to 400 copies/mL, but not in those with less than 20 copies/mL 152 (15). Our findings also indicate that the cART regimen we employed (18) was robust enough 153
to halt viral evolution nearly completely in animals. 154
Our sample size, an average of 10 sequences from each specimen, conceivably 155 limited our ability to detect minor populations with signs of ongoing replication. An analysis 156 of four animals, however, did not reveal the genotypes detailed in the current study. 
